The new antimicrobial drug MRX-8 was funded by CARB-X for $7.78 million and approved by the FDA for Phase I clinical trials.

Introduction: Alliance Pharmaceuticals received $7.78 million in non-diluted funding from partners.
. Shanghai, China and Foster City, California, U.S., August 13, 2020 - Myer Pharmaceuticals today announced that its new antimicrobial drug MRX-8 has received up to $7.78 million in non-dilution funding from carB-X, a global partner, to support clinical Phase I trials and other related research.
, CARB-X has funded research related to MRX-8 U.S. Clinical Trial Application (IND).
pharmaceutical company also announced that the FDA has completed the MRX-8 Clinical Trial Application (IND) review, approved the first human clinical trial.
the CARB-X funding will be used to support Phase I clinical trials and the research necessary to support future Phase II clinical trials.
MRX-8 is a new type of polymyobacterial antimicrobial that is effective against infections caused by multi-drug-resistant (MDR) Terranean-negative bacteria, including carbon penicillin-resistant E. coli, copper-green protons, and Baumann's immobilized bacteria.
MRX-8 has the same antimicrobial spectrum as the existing drugs mucosal and polymicromycin B, the differentiation advantage is reduced renal toxicity and neurotoxicity.
polymicrobial class is currently the last line of defense against infection treatment drugs, in patients treated with mucosal and polymicrobial B, the occurrence of acute kidney injury-based renal toxicity can be as high as 60%.
MRX-8 has shown better kidney safety in a number of completed preclinical studies, including toxicology studies of non-human primates.
, MRX-8 also showed better efficacy than polyxycin B in animal models of Terrain-negative bacteria urinary tract and lung infections.
"We are pleased to work with CARB-X to meet the global demand for safer and more effective antimicrobials."
CARB-X is a non-profit partner of outstanding financial institutions and experts in the field of antimicrobial research and development, and we are very grateful for their generous financial and technical support.
Yuan Zhengyu, chairman and chief executive officer of Alliance Pharmaceuticals, said.
MRX-8 was discovered by a team of scientists at Myer Pharmaceuticals, which owns the global intellectual property rights for its compounds and uses.
this innovative molecule from the initial concept design, and now successfully completed the U.S. IND application, is about to launch the first human Phase I clinical trials, once again demonstrated the commitment of Amerindic Pharmaceuticals to develop new anti-drug bacteria.
MRX-8 is a powerful complement to the company's new drug Contezolid in the NDA phase and the new drug MRX-4 in phase II, forming the complete product pipeline for the treatment of severe Glorene-positive and negative bacterial infections.
about Alliance Pharmaceuticals Ltd. Alliance Pharmaceuticals is a private biotechnology company focused on the discovery and development of new anti-drug bacteria with better safety.
first product developed by
is a new generation of antimicrobial antimicrobials resistant to methicillin Staphylococcus aureus and reduces hematological adverse reactions to these antimicrobials through structural optimization.
Pharmaceuticals has completed two Phase II clinical trials of contide in China and the United States, and after successfully completing the first Phase III clinical trial of complex skin and soft tissue infections in China, a new drug listing application (NDA) was submitted in China at the end of 2019.
has established operations centers in Shanghai, China, and California, USA.
for more information, please visit: .
about CARB-XCARB-X is a global non-profit partner dedicated to accelerating early development of antimicrobials to address the growing threat of antibiotic resistance.
CARB-X is led by Boston University and provides in-kind support from the Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, the German Federal Department of Education and Research (BMBF), the UK Department of Health and Social Care's Global Antibiotic Resistance Innovation Fund (GAMRIF), the Bill and Melinda Gates Foundation, and the National Institute of Allergy and Infection (NIAID).
CARB-X will invest up to $500 million from 2016 to 2021 to support innovative antimicrobials and other therapeutic drugs, vaccines and rapid diagnostics.
CARB-X supports the world's largest and most innovative preclinical product pipeline for the treatment of drug-resistant bacterial infections.
CARB-X is headquartered at Boston University School of Law.
carb-x.org/.
please pay attention Twitter@CARB-X.
this press release is authorized by ASPR/BARDA's cooperation agreement number IDSEP160030 and the Wellcome Trust Fund.
this article is the author's independent responsibility and does not necessarily represent the official opinion of CARB-X, the HHS Office of the Assistant Secretary-General for Disaster Preparedness, or other CARB-X investors.
.